Weekly Quick Hits (BioHealth Capital Region) – Week of April 17, 2023 By Sarah Ellinwood, Alex Keown, and Mark TerryApril 21, 2023 Funding, Awards and Collaborations OpGen Enters Into Distribution [….]
Charlottesville’s ZielBio sets sights on $75M raise Email Facebook LinkedIn Twitter
Kimberly Kelly is the founder and CEO of ZielBio.
Meghan McSweeney
By James Shea – Richmond Inno
November 09, 2022, 01:20pm EST
Charlottesville’s ZielBio finalized a $15 million funding round this summer to complete initial trials of a cancer treatment drug it hopes to bring to market in 2024.
The genesis for the company started when founder and CEO Kimberly Kelly was completing a post-doctoral fellowship at Massachusetts General Hospital. She noticed a correlation in some cancers with the progression of cancer-specific plectin, a protein. The protein became more prevalent in part of cancer cells as certain cancers progressed. She began researching ways to target the plectin as a treatment.
Kelly took a position as a professor in biomedical engineering at the University of Virginia and continued her research. She developed a targeted treatment and initially talked to pharmaceutical companies about licensing the technology. Because the approach was new, the companies wanted to see more data. That meant spinning the technology off from the university and seeking private financing.
“The government and the institutions like the universities don’t have the money to do the $10 million for manufacturing and…
ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer and other serious diseases through its innovative ZielFind drug discovery platform, will present new, preclinical data on the efficacy of its ZB131 drug in cholangiocarcinoma (CCA) models at the American Association for Cancer Research (AACR) Annual Meeting 2022. The conference will take place April 8-13, 2022 in New Orleans and virtually. Dr. Lindsey Brinton, Head of Discovery at ZielBio, will present the data in a talk on Tuesday, April 12 at 3:05 in La Nouvelle Orleans C.
ZielBio Announces First Patient Dosed in Phase 1/2 Clinical Trial of ZB131, Its Novel Monoclonal Antibody Targeting Cancer Specific Plectin First-in-human, open-label, dose escalation study will evaluate ZB131 in patients [….]
ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer and other serious diseases through its innovative ZielFind drug discovery platform, welcomes Maria Beconi, Ph.D., as the company’s chief science officer, and Ramesh Ramanathan, M.D., as vice president for clinical development.
Biopharma and Life Science companies in the BioHealth Capital Region are known for their work with cutting edge technologies such as gene and cell therapies. Those strengths were on display at the 6th annual BioHealth Capital Region Forum.
At BioBuzz, we’re dedicated to bringing you interesting and important stories that emerge from the thriving life sciences ecosystem that is the BioHealth Capital Region (BHCR).
